

# FITCH, EVEN, TABIN & FLANNERY

ATTORNEYS AND COUNSELLORS AT LAW

*Established in 1859*

SUITE 401L - 1801 K STREET, NW  
WASHINGTON, D.C. 20006-1201

TELEPHONE (202) 419-7000

FACSIMILE (202) 419-7007

CHICAGO OFFICE

SUITE 1600 - 120 SOUTH LASALLE STREET  
CHICAGO, ILLINOIS 60603-3406  
TELEPHONE (312) 577-7000

CALIFORNIA OFFICE

SUITE 510 - 4250 EXECUTIVE SQUARE  
SAN DIEGO, CALIFORNIA 92037-9105  
TELEPHONE (858) 552-1311

COLORADO OFFICE

SUITE 213 - 1942 BROADWAY  
BOULDER, COLORADO 80302  
TELEPHONE (303) 402-6966

MORGAN L. FITCH, JR.  
FRANCIS A. EVEN\*  
JULIUS TABIN  
JOHN F. FLANNERY  
ROBERT B. JONES  
JAMES J. SCHUMANN  
JAMES J. HAMILL  
TIMOTHY E. LEVSTIK  
JOSEPH E. SHIPLEY  
ROBERT J. FOX  
KENNETH H. SAMPLES  
PHILIP T. PETTI  
JOSEPH T. NABOR  
STEVEN C. SCHROER  
RICHARD A. KABA\*  
KARL R. FINK  
MARK W. HETZLER  
TIMOTHY P. MALONEY  
PERRY J. HOFFMAN  
JAMES P. KRUEGER  
STEPHEN S. FAVAKEH  
EDWARD W. GRAY, JR.\*



BRUCE R. MANSFIELD  
SHERRI N. BLOUNT\*  
RICHARD E. WAWRZYNIAK  
CHARLES WILLIAM PETERSON, JR.  
KATHLEEN A. RANNEY  
KENDREW H. COLTON\*  
ROMI N. BOSE  
STEVEN G. PARMELEE

CHRISTOPHER E. GEORGE\*  
SCOTT J. MENGHINI  
EDWARD E. CLAIR  
PAMELA L. STEWART  
SANDRA V. SCAVO  
JON A. BIRMINGHAM  
RUDY KRATZ  
RAMON R. HOCH  
JOHN E. LYHUS  
STEVEN M. FREELAND  
DONNA E. BECKER

PATENT AGENTS

ERIC J. WHITESELL  
KURT J. FUGMAN  
JONATHAN H. BACKENSTOSE  
LILIA I. SAFONOV

OF COUNSEL

THOMAS F. LEBENS

\*ADMITTED TO D.C. BAR; D.C. PRACTICE  
OF ALL OTHERS LIMITED TO FEDERAL COURTS  
AND AGENCIES

August 6, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

Re: Amendment and Response  
Appl. No.: 09/873,409  
Filed: June 5, 2001  
Title: **A Gene Encoding a Multidrug Resistance  
Human P-Glycoprotein Homologue on  
Chromosome 7p15-21 and Uses Thereof**  
Inventor(s): Frank, *et al.*  
Atty. Dkt.: 7570/73298

Dear Sir:

The following documents are being forwarded herewith for appropriate action by the U.S.  
Patent and Trademark Office:

1. Amendment and Response Under 37 C.F.R. § 1.111;
2. Change of Address Notice; and
3. One return postcard.

RECEIVED

AUG 07 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents  
August 6, 2002  
Page 2

**CALCULATION OF ADDITIONAL FEES**

Applicant(s) have calculated additional fees as follows:


	No. After Amendment	No. Previously Paid for	No. Extra	Rate	Fee
Total Claims Fee	23	25=	0	\$ 18.00	0.00
Independent Claims Fee	5	5 =	0	\$ 78.00	0.00
Multiple Dependent Claims Fee (Previously Paid)	0	0	0	\$ 280.00	0.00
Total Additional Claims Fee					0.00
Extension of Time Fee					0.00
<b>TOTAL FEES DUE</b>					<b>0.00</b>

Applicants do not believe that any fees are due for the filing of these documents. However, The Commissioner is hereby authorized to charge any fee deficiency to our Deposit Account No. 06-1135 under Order No. 7570/73298.

It is respectfully requested that the enclosed postcard be stamped with the date the enclosed documents are received by the PTO and that it be returned as soon as possible.


Very truly yours,

FITCH, EVEN, TABIN & FLANNERY



Michael A. Sanzo  
Reg. No. 36,912  
Attorney for Applicants

MAS:ct  
Enclosures



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Frank, *et al.*

Appl. No.: 09/873,409

Filed: June 5, 2001

For: **A Gene Encoding a Multidrug  
Resistance Human P-Glycoprotein  
Homologue on Chromosome  
7p15-21 and Uses Thereof**

Art Unit: 1642

Examiner: Davis, N.

Atty. Dkt.: 7570/73298

#11/A  
JMY  
RECEIVED  
AUG 07 2002  
TECH CENTER 1600/2900

**Amendment and Response Under 37 C.F.R. § 1.111**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated May 7, 2002, Applicants respectfully request reconsideration of the above-captioned application in view of the following amendments and remarks.

**Amendments**

**In the Claims:**

Please cancel claims 5-7 and 9 without prejudice.

Please add new claims 18-40 as follows:

- A
18. A substantially pure polynucleotide consisting of a nucleotide sequence encoding a protein consisting essentially of an amino acid sequence selected from the group consisting of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; and SEQ ID NO:8.
19. The polynucleotide of claim 18, wherein said polynucleotide encodes a protein consisting essentially of the amino acid sequence of SEQ ID NO:1.